Finn
BMY Biopharma · Large cap · Pharma · Dividend · Thesis updated November 1, 2026

New medicines race incoming patent cliffs and price cuts

01 Running thesis

A hard handoff to newer drugs

Bristol-Myers Squibb is in a transition. Older blockbusters are losing protection, while newer drugs are trying to fill the hole. In the third quarter of 2026, management noted the Growth Portfolio now has eight blockbuster products.

The bull case points to commercial momentum and pipeline wins. Opdivo Qvantig reached a $1.3 billion annual run rate, helping defend market share against future biosimilars. The FDA also granted accelerated approval to Symvexis, a new multiple myeloma treatment.

The bear case highlights shrinking profit margins and upcoming revenue cliffs. Eliquis will lose European exclusivity in late 2026 ahead of a massive global drop expected in 2027. Orencia will face both Medicare price negotiations and a new biosimilar rival in 2028.

The next test is simple to state but hard to pass. The company must prove its new products can grow fast enough to beat lower prices, generic rivals, and late decade patent cliffs.

Oct 2026▲Third quarter 2026 earnings showed pipeline progress, including the FDA approval of Symvexis. The Admilparant 60mg dose met its primary endpoint, though the 120mg dose missed.
Jul 2026▲BMY raised full year guidance as the Growth Portfolio reached nearly 60 percent of revenue. The company also announced AI partnerships with Anthropic and NVIDIA to speed up drug discovery.
Apr 2026▲Cobenfy launched with $163 million in first quarter revenue, giving BMY a stronger early proof point in neuroscience.
Apr 2026→The first quarter of 2026 showed the core tradeoff more clearly. The Growth Portfolio kept growing, but Eliquis benefited from inventory build before a price cut.
Feb 2026▼The 2025 10-K added pressure to the pricing story. BMY disclosed a U.S. government agreement that included providing Eliquis to Medicaid for free starting January 1, 2026.
Oct 2025▲The third quarter of 2025 showed the Growth Portfolio dollar growth outpacing Legacy Portfolio erosion.
Jul 2025▲The second quarter of 2025 was a positive inflection point because Growth Portfolio gains exceeded Legacy Portfolio declines.
Apr 2025▼The first quarter of 2025 confirmed that Medicare Part D redesign was already hurting U.S. Eliquis pricing.
02 Business model

Patents turn science into sales

Bristol-Myers Squibb makes money by selling prescription drugs that are protected by patents. These drugs treat serious diseases in oncology, hematology, immunology, cardiovascular disease, and neuroscience.

The model can be very profitable while patents last. It breaks quickly when a top drug loses exclusivity, which means cheaper generic or biosimilar versions can enter the market. That is already happening with Revlimid and Pomalyst.

Management is trying to make the company leaner at the same time. A strategic productivity initiative targets $2 billion in cost savings by the end of 2027. The company is using shorter research cycle times and commercial efficiencies to reach that goal.

The company also partners for growth when it needs to. BMY recently secured artificial intelligence agreements with Anthropic and NVIDIA to speed up drug discovery and improve decision making.

03 Product portfolio

Where the drug mix is shifting

Cash cow

Eliquis

Eliquis is a major blood thinner and faces a loss of exclusivity in Europe in late 2026, followed by a steep global decline expected in 2027.

Cash cow

Opdivo and Opdivo Qvantig

Opdivo is a large cancer franchise. BMY is shifting patients toward the under the skin version called Qvantig, which has reached a $1.3 billion run rate.

Growth engine

Cobenfy

Cobenfy is a key neuroscience launch for schizophrenia. A major focus is educating doctors to increase patient doses for better results.

Growth engine

Symvexis

Symvexis received accelerated FDA approval in late 2026 as a new pill option for multiple myeloma.

Growth engine

Camzyos

Camzyos treats a heart condition that blocks blood flow. It recently expanded to pediatric patients and continues to grow quickly.

Growth engine

Reblozyl

Reblozyl treats anemia tied to certain blood disorders. It generated $750 million in the third quarter of 2026.

Cash cow

Revlimid and Pomalyst

These legacy blood cancer drugs are under heavy generic pressure. Generic erosion continues to drag down overall revenue for the older portfolio.

04 Business segments

Mostly a U.S. drug company

United States70%declining
International30%modest

The mix uses early 2026 revenue by geography: $7.8 billion from the United States and $3.4 billion from international markets. U.S. results are heavily exposed to Medicare price pressure.

05 Risk factors

What could break the bridge

Eliquis price and patent reset

High impact · High odds

Eliquis is a cash cow right now. However, the drug faces European exclusivity loss in late 2026 and a massive revenue step down in 2027 due to pricing changes.

We watchQuarterly Eliquis revenue and management comments on European sales.

Pipeline readout delays

High impact · Medium odds

Critical trial results for Milvexian and Cobenfy shifted to early 2027. Bad data would shrink the future growth bridge and limit the pipeline.

We watchMilvexian phase three readouts expected in early 2027.

Orencia double threat

High impact · High odds

Orencia will face federal price negotiations beginning in 2028. The company also allowed a subcutaneous biosimilar to launch in the U.S. around the same time.

We watchFederal negotiation lists and biosimilar launch updates for early 2028.

Legacy cliff steepens

High impact · High odds

Revlimid fell sharply in 2026 as generic competition widened in the U.S. while Pomalyst is also under pressure. If these decline faster than the Growth Portfolio rises, total revenue will fall.

We watchQuarterly sales for Revlimid and Pomalyst versus total Growth Portfolio revenue.

Opdivo defense may not hold

Medium impact · Medium odds

The company is pushing conversion to Opdivo Qvantig, reaching 17 percent market share in the U.S. recently. The open question is if Qvantig can protect market share against future biosimilars.

We watchOpdivo Qvantig total sales and patient conversion rates.
06 Quick answers

In one breath

Why is Bristol-Myers Squibb under pressure?

Several older drugs are losing exclusivity, which lets cheaper rivals take share. At the same time, U.S. pricing pressure is rising for drugs like Eliquis, Pomalyst, and Orencia.

What is the main bull case for BMY?

The bull case is that newer drugs can outgrow the legacy decline. The Growth Portfolio now includes eight products generating over $1 billion annually.

Why does Eliquis matter so much?

Eliquis is a massive blood thinner franchise that generates billions in revenue. A large revenue drop expected in 2027 is one of the clearest near term risks for the company.

What is Opdivo Qvantig?

Opdivo Qvantig is a version of Opdivo given under the skin instead of by IV infusion. BMY hopes it can make the franchise harder to displace as future competition rises.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Bristol-Myers Squibb Q3 2026 Earnings Transcript
  2. Bristol-Myers Squibb Q2 2026 Form 10-Q
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Bristol-Myers Squibb Company in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today